For example, in a phase 2 trial (NCT00965224), WT1 mRNA-electroporated dendritic cells in high-risk AML patients induced antileukemic responses in 13 of 30 cases, with improved 5-year OS in responders (53.8% vs. 25.0%; p = 0.01) linked to WT1-specific CD8+ T-cells—suggesting similar mRNA-DC platforms targeting tumor antigens could be adapted for MM [301] (Table 9). Here, WT1 is linked to acute myeloid leukemia.